Multicentre trial of naproxen and phenylbutazone in acute gout.

Abstract

SUMMARY Naproxen 750 mg as a single dose followed by 250 mg three times daily has been compared with phenylbutazone 200 mg four times daily for 48 hours followed by 200 mg three times daily for the treatment of acute gout in an open study on 41 patients.The drugs were equally effective with few and relatively mild side effects. Naproxen is a useful alternative agent for the treatment of acute gout.

Double‐blind trial of flurbiprofen and phenylbutazone in acute gouty arthritis.

“…Few comparative studies of non-steroidal antiinflammatory drugs have been undertaken in acute gout, but indomethacin (Smyth & Percy, 1973), naproxen (Sturge et al, 1977) and feprazone (Reardon et al, 1980) appear to be of similar efficacy to phenylbutazone, with a mean interval of approximately 4 days between the onset of treatment and resolution of the attack: an interval similar to that seen in the present study. Fenoprofen (Weiner et al, 1979) and ketoprofen (Siegmeth & Placheta, 1976) were also considered to be of similar efficacy to phenylbutazone, but the data did not include the duration of attack following initiation treatment.…”

2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis

“…The FDA has approved naproxen (Evidence A) (33, 34), indomethacin (Evidence A) (26, 27, 31, 32), and sulindac (Evidence B) (35) for the treatment of acute gout. However, analgesic and anti-inflammatory doses of other NSAIDs may be as effective (Evidence B–C).…”

Gout treatment: What is evidence-based and how do we determine and promote optimized clinical care?

“…Although only a few open-label studies have reported quantitative results, nearly all have concluded clinical benefit associated with short-term NSAID therapy. Controlled studies have employed comparator groups that have included indomethacin [34][35][36][37], phenylbutazone [38][39][40][41][42][43], or a different dose of the study drug [44,45]. Although generally deemed beneficial with good tolerability, there have been no substantial differences between the study agents and comparator drugs.…”